Celularity Revenue and Competitors
Estimated Revenue & Valuation
- Celularity's estimated annual revenue is currently $76.2M per year.
- Celularity received $250.0M in venture funding in February 2018.
- Celularity's estimated revenue per employee is $217,000
- Celularity's total funding is $400M.
- Celularity has 351 Employees.
- Celularity grew their employee count by 24% last year.
What Is Celularity?
POSTPARTUM PLACENTA: THE FOUNDATION OF OUR SCIENCE - Celularity scientists were the first to recognize the human placenta as an untapped resource for innovation, one which is the basis of Celularity innovations in immuno-oncology, hematology, and regenerative medicine. Our seminal discovery of unique stem, progenitor, and immune cells from the placenta is the foundation of our dominating intellectual property position. With proprietary platform technology and operational expertise to harness the power of this remarkable organ, we developed a deep therapeutic pipeline across a broad range of indications. AMPLIFYING THE BODYS ABILITY TO REGENERATE - Celularity combines innovative assets and research in cell therapy, functional regeneration, and biosourcing to develop leading therapeutic products and services that treat serious, life-threatening diseases. We are harnessing the unique cells and biomaterials from the postpartum placenta to provide therapies that amplify the body's ability to fight disease, heal, and regenerate itself. For more information visit our website at www.celularity.comkeywords:N/A
Number of Employees
Employee Growth %
Celularity Inc. ... These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity...
Celularity believes that by harnessing the placenta's unique biology and ready availability, it can develop therapeutic solutions that address...
Celularity, the venture-backed developer of novel cell therapies for cancer treatments, has received an initial clearance from the Food and Drug Administration to begin early-stage clinical trials on a potential treatment for COVID-19. The company, which has raised at least $290 million to date ...
A spinout of Celgene, Celularity made big news in February 2018, when it raised $250 million to accelerate development of its stem cell ...
WARREN, N.J.--(BUSINESS WIRE)--Celularity, Inc. (“Celularity” or the “Company”), a clinical-stage cell therapeutics company developing ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|